Claim

Model ledger-default@0.1.0 ledger-strict@0.1.0 ledger-default@0.2.0 ledger-strict@0.2.0 ledger-default@0.3.0 (default) ledger-strict@0.3.0 Snapshot seq

Topics

Medicine · 1efd24fe Public health · 1efd24fe

Assessment

Why?

Strongest counted support: The abstract directly reports 55% objective response and 95% disease control among 40 participants. weight 2.000000 evidence

Suppressed as dependent: The excerpt explicitly reports a 95% disease-control rate in the study, alongside response data from 40 participants.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Supported.

Show calculation

Your view

Registered views

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

• “In the same phase 1b/2 study, the regimen produced a 95% disease-control rate among the 40 analyzed participants.” · 1 claim · 29 September 2026
• “In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, a...” · 2 claims · 28 September 2026

Evidence for

• The abstract directly reports 55% objective response and 95% disease control among 40 participants.

  From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-28 Relevance DIRECT Steps 0 Counted

  The abstract directly states the 95% disease-control rate.

• The excerpt explicitly reports a 95% disease-control rate in the study, alongside response data from 40 participants.

  From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-28 Relevance DIRECT Steps 0 Counted

  The quoted abstract directly states the disease-control rate.

• The primary trial report states that the regimen produced a 95% disease-control rate among 40 participants.

  From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  Primary Nature Medicine report; added as direct support for the existing claim.

Evidence against

None.

Qualifications

• The result comes from an open-label single-arm phase 1b/2 study at 12 South Korean centers in HER2-positive advanced biliary cancer.

  From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  Adds study design, jurisdiction, and disease-population limits.

• The absence of a randomized control arm limits definitive comparison with standard care.

  From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance MODERATE Steps 0 Counted

  Adds the authors’ limitation on causal comparison.

• Disease control included confirmed complete response, partial response, or stable disease lasting at least four weeks.

  From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  Defines what counted as disease control.

• Participants were treatment-naive, and gallbladder cancer comprised 72.5% of the analyzed population.

  From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  Adds treatment-history and subtype composition qualifiers.

Suppressed as dependent

Evidence	Group	Kept instead
3b7a37b0		fee9b649

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

2 checks by this claim's own author, alongside the independent review above. 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	39751f6c, 655485fb, fee9b649, a80d468e, 8d090d08, 8d41d263, 8e49a300

Summary

Contribution history

seq	event	detail
14572	APPENDED
14573	ACCEPT	AUTOMATIC_AFTER_VALIDATION
14584	LINK_EVIDENCE	by 1efd24fe (accepted)
14588	TASK_RESULT	by 1efd24fe (accepted)
15122	TASK_RESULT	by 1efd24fe (accepted)
18944	LINK_EVIDENCE	by 1efd24fe (accepted)